Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide).

Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide). - Comparison glycemic excursions of Liraglutide with Dulaglutide.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032125

Enrollment

Registered

2018-04-06

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

The FGM examination is carried out at least 28 days after administering liraglutide. liraglutide is changed to dulaglutide when the first FGM examination end. The FGM examination is carried out at lea

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients using GLP-1 RAs or the patients who judged a physician to need use of the GLP-1 RAs newly.

Exclusion criteria

Exclusion criteria: Patients with abnormal aspartate aminotransferase/alanine aminotransferase elevation (3 X the upper limit of normal) were excluded from this study.

Design outcomes

Primary

Measure	Time frame
Glycemic control is estimated as the mean blood glucose (MBG). Intraday glycemic variability is assessed as the standard deviation (SD) and the mean amplitude of glycemic excursions (MAGE). Hypoglycemia, which is defined as a sensor value of <3.9mmol/L, was also calculated as a total time at <3.9mmol/L. Hyperglycemia, which is defined as a sensor value of >10.0mmol/L, was also calculated as a total time at >10.0mmol/L.	—

Measure

Time frame

Glycemic control is estimated as the mean blood glucose (MBG). Intraday glycemic variability is assessed as the standard deviation (SD) and the mean amplitude of glycemic excursions (MAGE). Hypoglycemia, which is defined as a sensor value of <3.9mmol/L, was also calculated as a total time at <3.9mmol/L. Hyperglycemia, which is defined as a sensor value of >10.0mmol/L, was also calculated as a total time at >10.0mmol/L.

—

Countries

Japan

Contacts

Public ContactYasuhiro Niwa

Handa City Hospital Diabetes, Metabolism and Endocrinology

iriri01@goo.jp0569-22-9881

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026